Cargando…

Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study

BACKGROUND: Paclitaxel regimen which is widely used in clinical treatment causes many negative physical and psychological consequences on women with breast cancer (BC). This longitudinal study firstly aimed to investigate symptom status, body perception changes, and the risk of anxiety and depressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Gokce Ceylan, Gamze, Gok Metin, Zehra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520499/
https://www.ncbi.nlm.nih.gov/pubmed/34657181
http://dx.doi.org/10.1007/s00520-021-06619-6
_version_ 1784584685175701504
author Gokce Ceylan, Gamze
Gok Metin, Zehra
author_facet Gokce Ceylan, Gamze
Gok Metin, Zehra
author_sort Gokce Ceylan, Gamze
collection PubMed
description BACKGROUND: Paclitaxel regimen which is widely used in clinical treatment causes many negative physical and psychological consequences on women with breast cancer (BC). This longitudinal study firstly aimed to investigate symptom status, body perception changes, and the risk of anxiety and depression in BC patients receiving during paclitaxel regimen. MATERIALS AND METHODS: This descriptive and prospective study was conducted with 84 BC patients receiving paclitaxel regimen. “Chemotherapy Symptom Assessment Scale (C-SAS),” “Body Perception Scale (BPS),” and “Hospital Anxiety and Depression Scale (HADS)” were applied at five time points (T(1), before the first Paclitaxel infusion; T(2), at the end of first cycle; T(3), at the end of fourth cycle; T(4), at the end of eighth cycle; T(5), at the end of twelfth cycle). Data was analyzed using descriptive statistics, Cochrane Q, and linear mix model regression analysis. RESULTS: The frequency of needling and numbness in hands and feet, pain, and skin or nail changes significantly increased in the subsequent assessment points (T(2), T(3), T(4), and T(5)) compared to the initial assessment (T(1)) (p < 0.05). The mean scores of BPS significantly decreased at T(2), T(4), and T(5) compared to T(1) (F = 8.152, p < 0.001). The mean scores of the anxiety subscale of the HADS scale decreased at the T(3), T(4), and T(5) compared to T(1) (F = 6.865, p < 0.001), and the mean scores of the depression subscale significantly increased at the T(5) compared to T(1) (F = 3.708, p = 0.006). CONCLUSIONS: The oncology nurse should comprehensively evaluate the patients who scheduled to receive paclitaxel treatment, and provide counseling to the patients during these specific weeks. Better management of the symptoms that increase with the paclitaxel regimen with repeated interviews under the supervision of the nurse will also prevent the deterioration of body perception. In addition, since the risk of depression increases over time in patients receiving paclitaxel, nurses should periodically screen the risk of depression, and timely consult the patients for the appropriate support.
format Online
Article
Text
id pubmed-8520499
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-85204992021-10-18 Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study Gokce Ceylan, Gamze Gok Metin, Zehra Support Care Cancer Original Article BACKGROUND: Paclitaxel regimen which is widely used in clinical treatment causes many negative physical and psychological consequences on women with breast cancer (BC). This longitudinal study firstly aimed to investigate symptom status, body perception changes, and the risk of anxiety and depression in BC patients receiving during paclitaxel regimen. MATERIALS AND METHODS: This descriptive and prospective study was conducted with 84 BC patients receiving paclitaxel regimen. “Chemotherapy Symptom Assessment Scale (C-SAS),” “Body Perception Scale (BPS),” and “Hospital Anxiety and Depression Scale (HADS)” were applied at five time points (T(1), before the first Paclitaxel infusion; T(2), at the end of first cycle; T(3), at the end of fourth cycle; T(4), at the end of eighth cycle; T(5), at the end of twelfth cycle). Data was analyzed using descriptive statistics, Cochrane Q, and linear mix model regression analysis. RESULTS: The frequency of needling and numbness in hands and feet, pain, and skin or nail changes significantly increased in the subsequent assessment points (T(2), T(3), T(4), and T(5)) compared to the initial assessment (T(1)) (p < 0.05). The mean scores of BPS significantly decreased at T(2), T(4), and T(5) compared to T(1) (F = 8.152, p < 0.001). The mean scores of the anxiety subscale of the HADS scale decreased at the T(3), T(4), and T(5) compared to T(1) (F = 6.865, p < 0.001), and the mean scores of the depression subscale significantly increased at the T(5) compared to T(1) (F = 3.708, p = 0.006). CONCLUSIONS: The oncology nurse should comprehensively evaluate the patients who scheduled to receive paclitaxel treatment, and provide counseling to the patients during these specific weeks. Better management of the symptoms that increase with the paclitaxel regimen with repeated interviews under the supervision of the nurse will also prevent the deterioration of body perception. In addition, since the risk of depression increases over time in patients receiving paclitaxel, nurses should periodically screen the risk of depression, and timely consult the patients for the appropriate support. Springer Berlin Heidelberg 2021-10-17 2022 /pmc/articles/PMC8520499/ /pubmed/34657181 http://dx.doi.org/10.1007/s00520-021-06619-6 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Gokce Ceylan, Gamze
Gok Metin, Zehra
Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study
title Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study
title_full Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study
title_fullStr Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study
title_full_unstemmed Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study
title_short Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study
title_sort symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520499/
https://www.ncbi.nlm.nih.gov/pubmed/34657181
http://dx.doi.org/10.1007/s00520-021-06619-6
work_keys_str_mv AT gokceceylangamze symptomstatusbodyperceptionandriskofanxietyanddepressioninbreastcancerpatientsreceivingpaclitaxelaprospectivelongitudinalstudy
AT gokmetinzehra symptomstatusbodyperceptionandriskofanxietyanddepressioninbreastcancerpatientsreceivingpaclitaxelaprospectivelongitudinalstudy